Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Exclusion Criteria

• •Patient with relapse ever treated by radiotherapy
• •Other prospective study's participation
• •Recent and massive digestive haemorrhage
• •Medical contra-indication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing.
• •Pre-existent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial syndrome)
• •Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion.
• •Ophthalmic pathology antecedent concerning the ocular surface or lens-carrier
• •Concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization
• •Less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets at inclusion
• •Bilirubin at higher concentration than one point five times the normal
• •Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with Cockroft's formula
• •Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the study
• •Pregnant or nursing women
• •Patient under guardianship or trusteeship.